• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID‐19 vaccine: another piece of SARS‐CoV‐2 skin puzzle?

Emily

Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242437/
Mazzatenta C, Piccolo V, Pace G, Romano I, Argenziano G, Bassi A. Purpuric lesions on the eyelids developed after BNT162b2 mRNA COVID-19 vaccine: another piece of SARS-CoV-2 skin puzzle?. J Eur Acad Dermatol Venereol. 2021;35(9):e543-e545. doi:10.1111/jdv.17340
Dear Editor,

Vaccination against SARS‐CoV‐2 has spread around the world since December 2020. Herein, we describe three patients, with no history of SARS‐CoV‐2 infection, who developed skin reactions after receiving Pfizer‐BioNTech (New York, NY, USA) COVID‐19 vaccine. The first patient was a 44‐year‐old woman who presented with purpuric lesions on the right and left eyelid, respectively, 21 and 25 days after the second dose of the BNT162b2 mRNA vaccine (Fig. 1c,d). The lesions were circumscribed on the upper eyelid, totally asymptomatic and resolved spontaneously after ten days. The second patient was a 63‐year‐old man who presented similar lesions on the upper eyelid three weeks after the second dose of the vaccine (Fig. 1a,b). The lesions were asymptomatic as well and resolved spontaneously after 15 days. Both patients had complete laboratory evaluation for coagulation disorders that resulted unremarkable.

(Photos at link.)
 
Back
Top Bottom